Literature DB >> 2003710

The changing prognosis of classic hemophilia (factor VIII "deficiency").

P K Jones1, O D Ratnoff.   

Abstract

OBJECTIVE: To estimate relative risk of mortality and median life expectancy for patients with classic hemophilia by a life-table analysis, taking into account deaths that may have occurred in infancy or childhood before the onset of symptoms.
DESIGN: Retrospective chart review of clinical series.
SETTING: Referral-based university medical center. PATIENTS: Seven hundred one patients with classic hemophilia (hemophilia A; factor VIII "deficiency") were studied for the years from 1900 to 1990; patients were identified in 289 families.
MEASUREMENTS AND MAIN RESULTS: Relative risk for mortality and median life expectancy among hemophiliacs were compared with those among normal U.S. males. Overall, mortality (relative to that of contemporaneous U.S. males) was increased about sixfold among severely affected patients, more than twofold among moderately affected patients, and was equivalent to that of U.S. males among mildly affected patients. Median life expectancy at 1 year of age had reached almost 68 years in the decade 1971 to 1980, but declined to only 49 years in the decade 1981 to 1990.
CONCLUSIONS: After improvement in survival from 1971-1980 (corresponding to widespread treatment with lyophilized concentrates of antihemophilic factor [factor VIII]), relative mortality is now increasing, especially among severely affected patients, in large measure because of the acquired immunodeficiency syndrome (AIDS).

Entities:  

Mesh:

Year:  1991        PMID: 2003710     DOI: 10.7326/0003-4819-114-8-641

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  7 in total

1.  Prophylaxis use among males with haemophilia B in the United States.

Authors:  M Ullman; Q C Zhang; S D Grosse; M Recht; J M Soucie
Journal:  Haemophilia       Date:  2017-08-06       Impact factor: 4.287

2.  The importance and challenge of pediatric trials of hemophilia drugs.

Authors:  Dirk Mentzer; Emilie Desfontaine; Paolo A Tomasi
Journal:  Nat Med       Date:  2014-05       Impact factor: 53.440

3.  The Ethics of Paid Plasma Donation: A Plea for Patient Centeredness.

Authors:  Albert Farrugia; Joshua Penrod; Jan M Bult
Journal:  HEC Forum       Date:  2015-12

4.  Heterosexual and mother-to-child transmission of AIDS in the hemophilia community.

Authors:  T L Chorba; R C Holman; B L Evatt
Journal:  Public Health Rep       Date:  1993 Jan-Feb       Impact factor: 2.792

5.  Direct and indirect estimation of the sex ratio of mutation frequencies in hemophilia A.

Authors:  J Oldenburg; R Schwaab; T Grimm; K Zerres; P Hakenberg; H H Brackmann; K Olek
Journal:  Am J Hum Genet       Date:  1993-12       Impact factor: 11.025

6.  The effect of factor VIII deficiencies and replacement and bypass therapies on thrombus formation under venous flow conditions in microfluidic and computational models.

Authors:  Abimbola A Onasoga-Jarvis; Karin Leiderman; Aaron L Fogelson; Michael Wang; Marilyn J Manco-Johnson; Jorge A Di Paola; Keith B Neeves
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

Review 7.  The legacy of haemophilia: Memories and reflections from three survivors.

Authors:  Albert Farrugia; Cees Smit; Andrea Buzzi
Journal:  Haemophilia       Date:  2022-05-19       Impact factor: 4.263

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.